Statement: A patient in cohort 2 of the primary trial received a Plasma transfusion.
Primary_evidence: Adverse Events 1:   Total: 15/131 (11.45%)   Disseminated intravascular coagulation 1/131 (0.76%)   Febrile neutropenia 5/131 (3.82%)   Hemoglobin decreased 7/131 (5.34%)   Lymphatics 1/131 (0.76%)   Transfusion: pRBCs 0/131 (0.00%)   Arrhythmia supraventricular 0/131 (0.00%)   Cardiac disorder 1/131 (0.76%)   Edema 0/131 (0.00%)   Left ventricular failure 0/131 (0.00%)   Myocardial ischemia 1/131 (0.76%) Adverse Events 2:   Total: 17/181 (9.39%)   Disseminated intravascular coagulation 0/181 (0.00%)   Febrile neutropenia 1/181 (0.55%)   Hemoglobin decreased 13/181 (7.18%)   Lymphatics 0/181 (0.00%)   Transfusion: pRBCs 1/181 (0.55%)   Arrhythmia supraventricular 1/181 (0.55%)   Cardiac disorder 0/181 (0.00%)   Edema 0/181 (0.00%)   Left ventricular failure 1/181 (0.55%)   Myocardial ischemia 0/181 (0.00%)